---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-24-034565"
form_type: "8-K"
ticker: "ZVRA"
cik: "0001434647"
company_name: "ZEVRA THERAPEUTICS, INC."
filed_at: "2024-11-12T23:59:59+00:00"
generated_at: "2026-05-30T01:43:11.769418+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Zevra Q3 net loss $33.2M; FDA approval of MIPLYFFA for NPC marks key milestone

## Summary
- Net loss of $33.2M ($0.69 per share) vs. $10.4M loss in Q3 2023; revenue $3.7M from French EAP and AZSTARYS royalties.
- FDA approved MIPLYFFA (arimoclomol) on Sept. 20 for Niemann-Pick type C; first-ever NPC drug approved.
- Cash, equivalents, and investments $95.5M as of Sept. 30; cash runway forecast into 2027, excluding PRV sale.
- Completed $64.5M public offering of 10.6M shares at $6.50; closed Iowa/Virginia labs, outsources early R&D.
- OLPRUVA revenue minimal; 90 prescription enrollment forms for MIPLYFFA received by Oct. 31, 30% approved for reimbursement.

## SEC filing metadata
- accession: 0001437749-24-034565
- form_type: 8-K
- ticker: ZVRA
- cik: 0001434647
- company_name: ZEVRA THERAPEUTICS, INC.
- filed_at: 2024-11-12T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1434647/000143774924034565/0001437749-24-034565-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1434647/000143774924034565/zvra20240819_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-24-034565
- JSON: https://secwatch.observer/filing/0001437749-24-034565.json
- Plain text: https://secwatch.observer/filing/0001437749-24-034565.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.